Related Experiment Video
Updated: Jan 11, 2026
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Use of Cangrelor for Patients Undergoing Coronary Artery Bypass Grafting: Insights From the CAMEO Registry
Jennifer A Rymer1, Courtney Page2, Brooke Alhanti2
1Division of Cardiology, Duke University, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA.
Insights
Cangrelor use in acute myocardial infarction (AMI) patients undergoing coronary artery bypass grafting (CABG) varies. Cangrelor treatment was associated with shorter hospital stays and time to CABG.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Limited data exists on cangrelor utilization in acute myocardial infarction (AMI) patients undergoing coronary artery bypass grafting (CABG).
- Understanding cangrelor use patterns is crucial for optimizing treatment strategies in this population.
Purpose of the Study:
- To investigate the characteristics and utilization patterns of cangrelor in patients with AMI undergoing CABG.
- To analyze cangrelor dosing strategies and patient outcomes within the CAMEO registry.
Main Methods:
- Retrospective analysis of the multicenter CAMEO registry, focusing on AMI patients who underwent CABG.
- Categorization of cangrelor dosing as "bridge" (≤1 μg/kg/min) or percutaneous coronary intervention (PCI) (>1 and ≤4 μg/kg/min).
- Exclusion of patients receiving cangrelor post-CABG.
Main Results:
- 42.3% of 246 CABG patients received cangrelor.
- Cangrelor use was associated with higher rates of PCI during hospitalization and less radial access.
- Cangrelor-treated patients had shorter times from admission to CABG and shorter overall hospital stays.
Conclusions:
- Cangrelor utilization in AMI patients undergoing CABG is diverse, with significant use of "bridge" dosing.
- Shorter hospital admission to CABG times and overall length of stay were observed in cangrelor-treated patients.
- Further research is warranted to elucidate the full impact of cangrelor in this patient cohort.
Background:
Little is known about the use of cangrelor in patients with acute myocardial infarction (AMI) undergoing coronary artery bypass grafting (CABG).
Objectives:
The purpose of this study was to examine characteristics and patterns of cangrelor utilization of CABG patients in CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes), a multicenter registry of AMI patients receiving cangrelor and/or oral P2Y12 inhibitors.
Methods:
We examined characteristics and patterns of cangrelor utilization in AMI patients who underwent CABG. Patients receiving cangrelor post-CABG were excluded. "Bridge" dosing was defined as cangrelor ≤1 μg/kg/min and percutaneous coronary intervention (PCI) dosing (>1 and ≤ 4 μg/kg/min).
Results:
In CAMEO, 246 patients underwent CABG (42.3% received cangrelor). Of these, 30.9% received cangrelor only, 11.4% received an oral P2Y12 inhibitor and cangrelor, 8.9% received an oral P2Y12 inhibitor followed by cangrelor, 21.1% received an oral P2Y12 inhibitor only, and 36.6% received neither. The median age was 63 vs 66 years in cangrelor- vs non-cangrelor-treated patients. Patients treated with cangrelor were more likely to have PCI during hospitalization (P < 0.001) and less likely to have radial access (P = 0.005). Time from admission to CABG and overall length of stay was shorter for cangrelor- vs non-cangrelor-treated patients (median 3.8 vs 5.1 days; 10.5 vs 12.7 days). Among cangrelor-treated CABG patients, 26% received the "bridge" dose, 64% received the PCI dose, and 10% received a combination of both.
Conclusions:
Cangrelor use in patients with AMI undergoing CABG varies, with over 25% of cangrelor-treated patients receiving "bridge" dosing prior to CABG. Timing from hospital admission to CABG and overall length of stay were significantly shorter in cangrelor-treated patients.
More Related Videos
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Coronary Artery Disease IV: Preventive Measures
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care